StockTipsArenaBeta

BUY Zydus Lifesciences Limited — Somil Mehta, Sharekhan

BUYZydus Lifesciences Limited
Zydus Lifesciences share price target & all analyst calls

bySomil Mehta, SharekhanHorizon: NA (inferred Swing (≤2wk))7 Aug 2026via CNBC Awaaz.

Entry₹1,114.9Inferred
Target₹1,190
Total upside +6.74% (call closed)
Stop loss₹1,075-3.58% risk
Exit₹1,19011 Aug 2026, 2:00 pm
Target hit+6.74%0.00%upside left
Follow Somil Mehta for new calls(21% target hit, 253 closed calls)Get alertsWatch ZYDUSLIFE for new buy/sell callsGet alertsSee 149 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 11 Aug 2026
7 supporting6 neutral1 opposing
Supports the BUY call (7)

Macquarie Hikes Zydus Lifesciences' Target Ahead Of Q1 Results; Bets On New Business Buildout To Drive Growth

NewsNdtv-Profit·11 Aug · today

(opens in new tab)

Zydus Lifesciences Ltd has launched REVAHALE, which is India's first once-daily nebulised LAMA medication for COPD.

BSE · Company Update·10 Aug · today

(opens in new tab)

Zydus gets USFDA nod for surgical imaging drug, may get 6-month monopoly in $125 million US market

NewsCnbc-Tv18·4 Aug · 6d ago

(opens in new tab)

Zydus Lifesciences Ltd announced final approval from the USFDA for Indocyanine Green for Injection, including 180-days CGT exclusivity.

BSE · Company Update·4 Aug · 6d ago

(opens in new tab)

Zydus Lifesciences announced final approval from USFDA for Indocyanine Green for Injection, with 180-days CGT exclusivity.

NSE · Press Release·4 Aug · 6d ago

(opens in new tab)
Neutral / worth noting (6)

Zydus Lifesciences Limited has submitted a press release regarding its unaudited financial results for the quarter ended June 30, 2026. The filing is a disclosure under SEBI regulations.

NSE · Press Release·11 Aug · today

(opens in new tab)

Zydus Lifesciences Ltd has submitted a press release regarding its unaudited financial results for the quarter ended June 30, 2026, as per SEBI regulations.

BSE · Company Update·11 Aug · today

(opens in new tab)

Unaudited financial results for the quarter ended on June 30, 2026

BSE · Board Meeting·11 Aug · today

(opens in new tab)

Zydus Lifesciences Q1 Results Today: Time, Earnings Call, What To Watch, Share Price

NewsNdtv-Profit·11 Aug · today

(opens in new tab)

Market Pulse: Key triggers to watch before the August 11 trading session

NewsCnbc-Tv18·10 Aug · today

(opens in new tab)
Weighs against the BUY call (1)

Zydus Lifesciences received an order from the Superintendent of Stamps, Gandhinagar, demanding recovery of ₹53.47 million in deficient stamp duty and ₹55.07 million in penalties, totaling ₹108.54 mill

BSE · Company Update·29 Jul · 2w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Zydus Lifesciences

All analyst calls on Zydus Lifesciences

More from Somil Mehta, Sharekhan

Every call and its outcome